Markets:

Overview

News

Currencies

International

Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

36.82 -0.60 (-1.60%)

Streaming Delayed Price Updated: 9:52 AM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Friday's after hours session: top gainers and losers ↗

January 24, 2025

After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review ↗

January 17, 2025

Many stocks flashed buy signals as the major indexes rose to or above key levels.

Via Investor's Business Daily

Topics Economy

A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts ↗

January 16, 2025

Via Benzinga

NASDAQ:HRMY is not too expensive for the growth it is showing. ↗

December 16, 2024

HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) is not too expensive for the growth it is showing.

Via Chartmill

Analyst Expectations For Harmony Biosciences's Future ↗

October 29, 2024

Via Benzinga

Earnings Outlook For Harmony Biosciences ↗

October 28, 2024

Via Benzinga

Breaking Down Harmony Biosciences: 6 Analysts Share Their Views ↗

October 02, 2024

Via Benzinga

BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. ↗

January 13, 2025

Some companies saw their shares skyrocket on preliminary reports, but others took hits.

Via Investor's Business Daily

Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts

January 13, 2025

From Harmony Biosciences

Via Business Wire

Investors should take note of NASDAQ:HRMY, a growth stock that remains attractively priced. ↗

January 07, 2025

Don't overlook HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

Don't overlook NASDAQ:HRMY—it's a hidden gem with strong fundamentals and an attractive price tag. ↗

January 03, 2025

HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), an undervalued stock with good fundamentals.

Via Chartmill

Investors who lost money on Harmony Biosciences Holdings, Inc. should contact Levi & Korsinsky about an ongoing investigation - HRMY

December 17, 2024

Via ACCESSWIRE

Unveiling 6 Analyst Insights On Harmony Biosciences ↗

September 10, 2024

Via Benzinga

Analyst Expectations For Harmony Biosciences's Future ↗

August 06, 2024

Via Benzinga

A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts ↗

June 21, 2024

Via Benzinga

Harmony Biosciences Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HRMY

December 16, 2024

Via ACCESSWIRE

HRMY ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Harmony Biosciences Holdings, Inc. Shareholders Who Lost Money

December 13, 2024

Via ACCESSWIRE

Why Harmony Biosciences (HRMY) Stock Is Down 18% Today ↗

October 30, 2024

Harmony Biosciences shares are trading lower by 17% Wednesday afternoon. The company announced a public offering of up to 8 million common stock shares from selling shareholders.

Via Benzinga

Harmony Biosciences (HRMY) Q3 2024 Earnings Call Transcript ↗

October 29, 2024

HRMY earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Harmony Bio, The No. 1 Biotech Stock, Surged On Its 'High-Quality' Beat ↗

October 29, 2024

The company is focused on developing its pipeline of sleep and epilepsy drugs.

Via Investor's Business Daily

Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says ↗

September 10, 2024

UBS has initiated coverage on Harmony Biosciences with a Buy rating and a price target of $56. UBS highlights Harmony's potential for growth, projecting a 19% CAGR for Wakix sales through 2026.

Via Benzinga

Harmony Biosciences (HRMY) Q2 2024 Earnings Call Transcript ↗

August 06, 2024

HRMY earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

HRMY Stock Earnings: Harmony Biosciences Beats EPS, Beats Revenue for Q2 2024 ↗

August 06, 2024

HRMY stock results show that Harmony Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028

August 06, 2024

From Harmony Biosciences

Via GlobeNewswire

7 Cheap Biotech Stocks With Major Upside Potential ↗

July 09, 2024

While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks.

Via InvestorPlace

7 Undervalued Biotech Stocks to Buy for Big-Time Returns ↗

July 01, 2024

The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive.

Via InvestorPlace

7 Biotech Stocks to Buy on the Dip: June 2024 ↗

June 24, 2024

With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.

Via InvestorPlace

Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In ↗

May 14, 2024

Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028.

Via Benzinga

Topics Cannabis

Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript ↗

April 30, 2024

HRMY earnings call for the period ending March 31, 2024.

Via The Motley Fool

Topics Earnings

HRMY Stock Earnings: Harmony Biosciences Beats EPS, Misses Revenue for Q1 2024 ↗

April 30, 2024

HRMY stock results show that Harmony Biosciences beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.